Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has informed the Exchange regarding the appointment of Ms Sandhya Gadkari Sharma as Non-Executive Independent Director of the company w.e.f. August 25, 2026. The company also approved the allotment of 1,475 equity shares to eligible employees under the Entero Employee Stock Option Plan 2023. Additionally, the Board approved the revised tenure for the re-appointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors, subject to shareholder approval.

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has appointed Mr. Rajesh Shashikant Dalal as a Non-Executive Independent Director, effective August 25, 2026. The company has also approved the allotment of 1,475 equity shares to eligible employees under the Entero Employee Stock Option Plan 2023. The board has also approved the revised tenure for the re-appointment of two independent directors, subject to shareholder approval.

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has informed the Exchange regarding the allotment of 1475 shares to eligible employees under the Entero Employee Stock Option Plan 2023. The Board also approved the revised tenure of reappointment of two Independent Directors.

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026. The Board approved allotment of 1,475 Equity Shares to eligible employees and revised tenure of reappointment of Independent Directors.

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026. The Board approved allotment of 1,475 Equity Shares to eligible employees and revised tenure for reappointment of Independent Directors.

Entero Healthcare Solutions Limited

Entero Healthcare Solutions Limited has announced the closure of its trading window for Designated Persons and their immediate relatives, effective July 01, 2026. This is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The date for the Board Meeting to consider these results will be intimated subsequently.